SAN FRANCISCO, CA — June 17, 2002 —
Avandia® (rosiglitazone) appears to lower markers of cardiovascular inflammation — a precursor of atherosclerosis and heart disease — in diabetic patients. Blood-borne oxygen free radicals can injure vessel linings, initiating vascular inflammation that induces atherosclerosis and heart disease.
The investigators found that rosiglitazone, a widely used insulin sensitizer, has a profound inhibitory effect on oxygen free radicals. They reported their findings here Saturday at the annual meeting of the American Diabetes Association (ADA). Atherosclerosis is a leading cause of heart disease, which diabetics suffer at twice the rate of non-diabetics.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!